World Journal of
Pharmaceutical and Life Sciences

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Life Sciences
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
World Journal of Pharmaceutical and Life Sciences (WJPLS) has indexed with various reputed international bodies like : Google Scholar, Index Copernicus, Indian Science Publications, SOCOLAR, China, Cosmos Impact Factor, Research Bible, Fuchu, Tokyo. JAPAN, Scientific Indexing Services (SIS), Jour Informatics (Under Process), UDLedge Science Citation Index, Global Impact Factor (In Process), International Impact Factor Services, International Scientific Indexing, UAE, International Society for Research Activity (ISRA) Journal Impact Factor (JIF), Science Library Index, Dubai, United Arab Emirates, International Innovative Journal Impact Factor (IIJIF), Scientific Journal Impact Factor (SJIF), Eurasian Scientific Journal Index (ESJI), Indian citation Index (ICI), IFSIJ Measure of Journal Quality, International Scientific Indexing, UAE (ISI), Web of Science Group (Under Process), Directory of Research Journals Indexing, Scholar Article Journal Index (SAJI), International Scientific Indexing ( ISI ), Scope Database, 



*Thakur Hitesh, Dr. R.B Sharma, Twinkle Garg.


Diabetes mellitus is a term used to describe a set of disorders that alter the body's blood sugar, or glucose. Diabetes is caused by either a lack of insulin production by the pancreas or a lack of insulin response by the body's cells. Diabetes is divided into two categories. Type 1 Diabetes and Type 2 Diabetes are the two types of diabetes. Insulin shortage and hyperglycemia are symptoms of type 1 diabetes, which is an autoimmune disease. Insulin is a hormone produced by the pancreas that aids in the transport of glucose into the body's cells for energy use. In India, diabetes prevalence increased from 7.1 percent in 2009 to 8.9 percent in 2019. IGT is anticipated to affect 25.2 million adults, with that number expected to rise to 35.7 million by 2045.Diabetes affected 1.3 billion Indians, or about four times the population of the United States. In 2017, 72.9 million people in India had diabetes, up from 40.9 million in 2007. Sodium-glucose co-transporter-2 (SGLT2) inhibitors (SGLT2i) are one of the most promising novel anti-diabetics, gaining attention even outside of its usual prescription for type 2 diabetes (T2DM). SGLT2 is a low-affinity, high-capacity glucose transporter that is expressed apically in proximal convoluted tubule epithelial cells and reabsorbs 90% of filtered glucose. SGLT2 inhibitors are a family of winkle GArgprescription drugs that have been licensed by the FDA for use in adults with type 2 diabetes in conjunction with diet and exercise to control blood sugar levels.

[Full Text Article]


World Journal of Pharmaceutical and life sciences Will give best paper award in every issue in the from of money along with certificate to promote research .

Best Article of current issue

Download Article : Click here